GNOM 📈 Global X Genomics & - Overview
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US37954Y4347 • Health
GNOM: Genomics, Biotechnology, Pharmaceuticals, Diagnostics, Research, Therapies
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified. ‣ Company URL: ‣ Domicile:
Additional Sources for GNOM ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GNOM ETF Overview
| Market Cap in USD | 78m |
| Category | Health |
| TER | 0.50% |
| IPO / Inception | 2019-04-05 |
GNOM ETF Ratings
| Growth 5y | -55.5% |
| Fundamental | - |
| Dividend | 1.0% |
| Rel. Strength Industry | -138 |
| Analysts | - |
| Fair Price Momentum | 8.27 USD |
| Fair Price DCF | - |
GNOM Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 5.2% |
GNOM Growth Ratios
| Growth Correlation 3m | -68.3% |
| Growth Correlation 12m | -35.7% |
| Growth Correlation 5y | -79.8% |
| CAGR 5y | -9.34% |
| CAGR/Mean DD 5y | -0.24 |
| Sharpe Ratio 12m | -0.60 |
| Alpha | -43.58 |
| Beta | 1.13 |
| Volatility | 37.18% |
| Current Volume | 111.7k |
| Average Volume 20d | 80.8k |
What is the price of GNOM stocks?
As of December 22, 2024, the stock is trading at USD 9.89 with a total of 111,663 shares traded.
Over the past week, the price has changed by -3.70%, over one month by +0.71%, over three months by -12.63% and over the past year by -11.16%.
As of December 22, 2024, the stock is trading at USD 9.89 with a total of 111,663 shares traded.
Over the past week, the price has changed by -3.70%, over one month by +0.71%, over three months by -12.63% and over the past year by -11.16%.
Is Global X Genomics & a good stock to buy?
No, based on ValueRay Analyses, Global X Genomics & (NASDAQ:GNOM) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -55.46 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GNOM as of December 2024 is 8.27. This means that GNOM is currently overvalued and has a potential downside of -16.38%.
No, based on ValueRay Analyses, Global X Genomics & (NASDAQ:GNOM) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -55.46 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GNOM as of December 2024 is 8.27. This means that GNOM is currently overvalued and has a potential downside of -16.38%.
Is GNOM a buy, sell or hold?
Global X Genomics & has no consensus analysts rating.
Global X Genomics & has no consensus analysts rating.
What are the forecast for GNOM stock price target?
According to ValueRays Forecast Model, GNOM Global X Genomics & will be worth about 9.2 in December 2025. The stock is currently trading at 9.89. This means that the stock has a potential downside of -6.67%.
According to ValueRays Forecast Model, GNOM Global X Genomics & will be worth about 9.2 in December 2025. The stock is currently trading at 9.89. This means that the stock has a potential downside of -6.67%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 9.2 | -6.7% |